Charles River Laboratories International, Inc.
CRLLast close · Oct 16, 2026300.15−6.09 (−1.99%)
Market cap$14.5B
11 firms' latest targets, last 90 days: median $330.00 ($295.00–$357.00), 10% above the last close.
Price and published targets
Each firm's latest target
| Date | Firm | Target | Change | Vs price now |
|---|---|---|---|---|
| 2026-10-12 | Morgan Stanley | $340.00 | ▲ 13% | +13% |
| 2026-09-30 | UBS | $357.00 | — | +19% |
| 2026-09-28 | Jefferies | $340.00 | — | +13% |
| 2026-09-25 | Deutsche Bank | $320.00 | — | +7% |
| 2026-09-25 | RBC Capital | $322.00 | ▲ 14% | +7% |
| 2026-09-25 | Evercore ISI | $330.00 | ▲ 3% | +10% |
| 2026-09-25 | Baird | $334.00 | ▲ 15% | +11% |
| 2026-09-25 | Mizuho Securities | $295.00 | ▲ 12% | -2% |
| 2026-09-25 | Barclays | $330.00 | ▲ 10% | +10% |
| 2026-09-17 | Argus Research | $330.00 | ▲ 65% | +10% |
| 2026-08-10 | Piper Sandler | $300.00 | — | +0% |
Consensus estimates
| FY | Revenue | YoY | EPS | YoY | Revenue range | EPS range | Analysts |
|---|---|---|---|---|---|---|---|
| 2023reported | $4.1B | +4% | $9.22 | -3% | est. $4.1B+1% | est. $10.59 | 11 |
| 2024reported | $4.0B | -2% | $0.20 | -98% | est. $4.0B+0% | est. $10.18 | 12 |
| 2025reported | $4.0B | -1% | -$2.91 | -1555% | est. $4.0B+0% | est. $10.24 | 11 |
| 2026 | $3.9B | -2% | $11.37 | +11% | $3.9B–$4.0B | $11.19–$11.50 | 9 |
| 2027 | $4.0B | +3% | $12.82 | +13% | $4.0B–$4.1B | $12.07–$13.03 | 12 |
| 2028 | $4.3B | +6% | $14.38 | +12% | $4.1B–$4.4B | $10.08–$17.68 | 12 |
| 2029 | $4.5B | +6% | $16.43 | +14% | $4.4B–$4.6B | $16.10–$16.76 | 6 |
| 2030 | $4.8B | +6% | $17.65 | +7% | $4.7B–$4.9B | $17.30–$18.01 | 10 |
Targets, grades and estimates are quoted from third parties (via Financial Modeling Prep) and are theirs, not ours; each target links to the report it was published in. A firm counts once, at its latest target or grade.